EP1439860A1 - Magnetic nanodispersion comprising cyclodextrines and method for the production thereof - Google Patents
Magnetic nanodispersion comprising cyclodextrines and method for the production thereofInfo
- Publication number
- EP1439860A1 EP1439860A1 EP02772398A EP02772398A EP1439860A1 EP 1439860 A1 EP1439860 A1 EP 1439860A1 EP 02772398 A EP02772398 A EP 02772398A EP 02772398 A EP02772398 A EP 02772398A EP 1439860 A1 EP1439860 A1 EP 1439860A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- groups
- magnetic
- magnetic dispersion
- water
- bioactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/189—Host-guest complexes, e.g. cyclodextrins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
Definitions
- the invention relates to a magnetic dispersion and a method for its production in accordance with the preambles of claims 1 and 15.
- Magnetic dispersions are liquid, stable dispersions with magnetic, in particular superparamagnetic, properties.
- the core particles are composed of ferro- or ferrimagnetic substances, such as magnetite, maghemite and their mixtures, and ferrites of the formula
- Me (II) 0. Fe (III) 2 0 3 , where Me (II) is a metal ion such as Co, Mn.
- Me (II) is a metal ion such as Co, Mn.
- shells made of non-magnetic molecules or polymers which are chemically fixed to the particle surface of the core particles, the adsorbents
- aqueous magnetic dispersions the particles of which consist of a double layer of fatty acids and combinations of fatty acids with e.g. B. non-ionic surfactants, such as ethoxylated fatty alcohols, but which are not biologically compatible.
- biocompatible magnetic fluids have gained particular importance in recent years. These include aqueous magnetic dispersions with nanoparticles which are coated with polysaccharides (US 4,452,773, WO 91/02811, DE-OS 3443252).
- magnetic nanoparticles which are stabilized with derivatives of the polysaccharides, such as with polyaldehyde dextran (US 6 231 982), aminodextran (WO 99/19731), carboxy dextran (EU 0284549).
- dextrins are clearly dextrins with thread-like molecules with average molecular weights of 200 to 30,000, which, depending on the solvent, are more or less gnawed. They are also known as "linear" dextrins.
- ⁇ -, ⁇ - and ⁇ -cyclodextrins are also described in detail, also as constituents of inclusion compounds for small molecules (W. Saenger, Angew. Chem. 92, 343-361 (1980)). All are toxicologically safe.
- the cyclodextrins are ring-shaped oligosaccharides made from (1- 4) glucose units, which contain, for example, six, seven or eight glucose units (up to 12 possible). You have a lot uniform molecular weights of 972, 1135 and 1297. ⁇ - and ⁇ -cyclodextrins are very water-soluble. A special feature is that these connections form channel-like or cage-like supramolecular structures, ie 0.5 - 0.8 nm narrow cavities into which liquids and solids can be enclosed (nano-encapsulations).
- dispersions of magnetic nanoparticles which are surrounded by two polymer coating layers (DE 4428851 C2), which consist of an inner shell made of a synthetic polymer and an outer shell made of a target polymer.
- the layers can also be composed in the same way.
- Linear oligosaccharides and polysaccharides are mentioned here, in particular dextran and also carboxymethyl-dextrans.
- DE 19624426 A1 also describes magnetic nanoparticles which are stabilized in a dispersion liquid with crosslinked polysaccharides and their derivatives with molecular weights of 5,000-250,000.
- the dextran casings are modified using iodate in such a way that peptides (1-30 amino acids) are bound, which e.g. have a defined affinity for the HIV virus.
- EP 0928809 AI, EP 0525199 AI describes the preparation of carboxymethyldextran, carboxymethylamminodextran and ether derivatives, monochloroacetic acid being used as the carboxylating agent. Magnetite volume percentages from 0 to 20 are claimed, which corresponds to a saturation polarization of up to 40 mT.
- Core particle diameters of 5-50 nm, preferably 6-15 nm, are mentioned.
- the biocompatible magnetic fluids produced according to the prior art have the following disadvantages: Polysaccharides and their derivatives are thread molecules. They are available in a broad molecular weight range, predominantly with molecular weights over 20,000, which are then only water-soluble to a limited extent. Their solubility is still greatly reduced in the presence of electrolytes. For the stabilization of magnetic nanoparticles in aqueous magnetic liquids, they are predominantly only suitable in adsorbed form in the acidic pH range. In the physiologically interesting pH ranges between 6.8-7.5, signs of coagulation already occur disadvantageously. All of the factors mentioned have a negative influence on the colloidal stability of the magnetic nanoparticles and thus also on the content of magnetic component or the saturation polarization, which hardly exceeds 5 mT. Technical applications are practically impossible.
- the object of the invention is to offer a magnetic dispersion which, with great biocompatibility, has a high saturation polarization and whose magnetic particles are suitable as transport vehicles for further pharmacologically and biologically active substances, and to propose a process for their preparation.
- the new magnetic dispersion consists of water or water-miscible dispersants in which the magnetic core particles are finely and stably distributed, with cyclodextrins and their derivatives as the coating component.
- vate according to the general formula M [A p , C, B q ] are used.
- a reactive groups B bioactive groups and
- the compound (A p .CjB g ) is fixed to the surface of the core particles via the reactive A group.
- Cyclodextrins whose reactive A groups are -H or - (CH 2 ) nR and their salts have been shown to be particularly advantageous with regard to achieving a high stability of the magnetic dispersion and a high saturation magnetization, where n can assume the values from 0 to 20 and R -H, - (OH), -CHOH-CH 3 , - (COOH), - (NH 2 ), - (SH),
- the number q of bioactive B groups is 0.
- the desired biocompatibility of the magnetic dispersion according to the invention or of the coating component cyclodextrin can already be achieved for certain applications without bioactive B groups. This is particularly true for applications in which the shell should not have any specific or selective properties.
- the number q of bioactive B groups is 0, only as many A groups are substituted as are necessary for binding to the core particles M.
- the degree of substitution per glucose molecule is between 0 and 3.
- compounds such as streptavidin, insulin, heparin, nucleic acids, antibodies and enzymes on the cyclodextrin ring are substituted as bioactive groups B.
- the cyclodextrins have only reactive groups A, ie the bioactive groups B are replaced by A.
- bioactive groups B on the cyclodextrins instead of reactive groups A or reactive A groups which protrude into the solution and are not fixed to the core particles M by further coupling of chemical ones or to modify biochemical compounds to form B groups.
- a very significant advantage of the magnetic dispersion according to the invention can be achieved by wrapping around the shell a secondary structure can be built up, which consists of several ordered cyclodextrin molecules of the general formula [ Ap , C, Bq ] k , where k can have values between 1 and 200. Because of this secondary structure forming on a core particle, it is possible to create cavities of different sizes, into which different substances can then be introduced and also desorbed again.
- the cyclodextrins C are unsubstituted, in particular -, ⁇ - and ⁇ -cyclodextrins with the defined molecular weights of 975, 1135 and 1297 being provided.
- the magnetic dispersions stabilized in this way have the advantage that the magnetic core particles with this shell can go into cancer cells without additional treatments, thereby making magnetic labeling possible.
- the magnetic core particles M are characterized in that they consist of maghemite and ferrites of the formula
- the magnetic dispersions composed according to the invention are used to set or achieve saturation polarizations between 0.05 and 80 mT with a size of the core particles M of 3 to 300 nm.
- the larger core particles are easier to manipulate in the magnetic field, and the dispersions with the larger particles have more advantageous viscosity properties.
- Suitable dispersants for the magnetic nanoparticles are water, including physiological aqueous solutions, dimethylformamide, polyhydric alcohols such as glycerol, ethylene glycol and polyethylene glycol or mixtures thereof.
- the magnetic dispersions according to the invention are produced by the following process steps
- a pH in the acidic range for example between 1 and 6, after the first washing process.
- Add substituted cyclodextrans at temperatures between 20 and 90 ° C. Differently substituted cyclodextrans can also be added in a two-stage process.
- the reactive A groups are -H and / or - (CH 2 ) nR and their salts, where n can assume the values from 0 to 20 and
- B groups for example groups that are derived from avidines such as streptavidin, such as insulin, heparin, nucleic acids, antibodies, oligopeptides, amino acids and enzymes.
- a compound of the general formula (A p , C) is used, the number of reactive A groups corresponding to the number of formation sites for the magnetic core particle M.
- a compound of the general formula (A p , C) is reacted with the magnetic core particles M and then the complex M [A p , C] formed is reacted with B q .
- a cyclodextrin C with the magnetic core particle M then the complex M [C] formed with a compound with active group A p and then the complex M [A p , C] formed with a compound with bioactive group B q to form M [A p , C, B q ].
- mixtures of compounds of the general formula (A p , C, B q ) are added, a compound of the general formula (A p , C, B q ) being added in a special embodiment and then in a second step a further compound of the general formula (A p , C, B q ) is added.
- active esters such as 1-ethyl- (3) - (3-diethylaminopropyl) carbodiimide, 1-cyclohexyl-3 (2-morpholinoethyl) carbodiimide, N-hydroxy- succinimide and dicyclohexylcarbodiimide used.
- the hydroxide is precipitated from a Me (II) salt solution in a manner known per se and then treated with an oxidizing agent, wherein for Me (II) divalent metal ions such as Fe 2+ , Co 2 + , Zn 2+ and Mn 2+ are available.
- Me (II) divalent metal ions such as Fe 2+ , Co 2 + , Zn 2+ and Mn 2+ are available.
- hydrogen peroxide or oxygen are used as the oxidizing agent.
- the process modified in this way can be used in particular to produce magnetic dispersions whose core particles have a size of approximately 150 nm.
- the magnetic dispersion can be treated with substrates X, so that these substrates X can be introduced into cavities formed in the shell of the magnetic nanoparticles, for example in the secondary structure that can be formed.
- substrates X are in particular compounds with pharmacological and / or biological activity the. These are substances such as antibiotics (penicillin), hormones (prostaglandins) or antitumor enzyme or antitumor proteins.
- aqueous dispersions of magnetic nanoparticles stabilized with cyclodextrins and their derivatives have a high colloidal stability of the particles and an achievable volume fraction of magnetic component of up to 20% or saturation polarizations of up to 80 mT.
- biocompatibility There is also an improved biocompatibility.
- These new properties are based, on the one hand, on the narrowly limited and low molecular weights from 972 to approx. 2,000 and the resulting low coating layer thicknesses and the better water solubility, as well as on their stability in physiologically important pH ranges. Additional advantages with new applications result from the cavities present in the particles, which can be used to absorb and transport foreign substances. They can be desorbed in a targeted manner at the destination, a property which is of great advantage when used as a "magnetic carrier".
- the magnetic dispersion according to the invention can be used in many ways.
- the biocompatibility was tested in mixtures with biological cells with the result that no or no significant impairment of the cell growth was observed.
- the magnetic dispersions according to the invention can be used both technically and for biological / medical purposes.
- the superparamagnetic volume properties are primarily used, i.e. the ability to move or fix the dispersion as a whole in the external magnetic field, such as for sealing purposes in magnetic liquid seals, to improve the performance of loudspeakers or to separate non-ferrous metals or for enrichment of ore components for swimming-sink sorting.
- the use is particularly appropriate when the biocompatibility of the particles can be used, e.g. in seals for rotary unions in the food industry, for the float-sink sorting of biological objects, including cells of different densities, in biotechnology or in medicine.
- the dispersion liquid consists of a solvent which is difficult to evaporate, e.g. from polyglycols or glycerin. Saturation polarizations of approx. 80 mT are achieved.
- the clinical applications relate to their already known use as contrast agents for liver metastases by means of ferromagnetic resonance methods or for the in vitro / in vivo coupling of bioactive molecules such as nucleic acids.
- Magnetic fluid hyperthermia is also known, in which cancer cells specifically decorated with magnetic particles are destroyed by overheating.
- the new magnetic fluids can be optimized for these applications, on the one hand by optimizing the core particle size and on the other hand with regard to the hydrodynamic particle radius, which allows the production of particles with narrow particle size dimensions. These optimizations are also important when optimizing immunoassays using magnetic relaxometry. It should be particularly emphasized that potentially new fields of application result from the fact that the adsorbed dextrins have cavities, in particular due to the formation of a secondary structure, in which selectable liquid and also solid foreign substances such as active substances, including pharmaceuticals, can be deposited. Magnetic conductive transportable complexes can thus be produced which are capable of various specific interactions, for example also with cells, including phagocytosis. The substances introduced can be desorbed at the site of action, for example in or on a cell.
- FIG. 1 shows a schematic representation of a possible structure of a magnetic nanoparticle
- FIG. 3 shows a schematic representation of the formation of a possible secondary structure in the shell
- FIG. 4 shows a schematic illustration of a possible secondary structure
- FIG. 5 shows a schematic illustration of a further possible secondary structure of the shell
- FIG. 6 shows a schematic illustration of a cyclodextrin molecule with the groups A and B and a substance X
- FIG. 7 shows a schematic illustration of a substituted one Cyclodextrin molecule which is bonded to the magnetic core particle M via an A group, wherein the B groups are bonded to the cyclodextrin ring via the reactive A groups
- FIG. 8 shows a schematic illustration of bonded A or B groups.
- the structure of a magnetic nanoparticle is shown schematically in the illustration according to FIG. 1.
- Substituted cyclodextrins with a reactive group A are fixed to the surface of the core particle M around a magnetic core particle M, while bioactive groups B protrude into a dispersing agent, not shown here.
- X symbolizes the position of a substance in the cyclodextrin ring.
- the cyclodextrin ring C shown in FIG. 2 shows that the reactive groups A or the bioactive groups B can be fixed to the groupings -OCH 2 .
- FIG. 3 schematically shows the formation of a secondary structure.
- the cyclodextrin molecules attach to one another to form a tunnel-like structure.
- a substance X can be introduced into this tunnel.
- FIG. 5 shows a further secondary structure in which the tunnel-like assemblies of the cyclodextrin molecules C with the bioactive groupings B and the reactive groups A effect fixation to the core particle M.
- a substance X can be introduced into the tunnel-like structures.
- 6 shows the groupings A and B in a possible constellation on a cyclodextrin molecule.
- FIG. 7 shows groups A and B in a possible constellation on a cyclodextrin molecule which is bonded to the surface of a magnetic core particle M.
- Cyclodextrins 10 g of ot-, ß- and ⁇ -cyclodextrin are taken up in 200 ml of isopropanol, heated to 40 ° C. with stirring and mixed with 6 g of NaOH, which is dissolved in 20 ml of water. 15 g of chloroacetic acid sodium salt, which is dissolved in 40 ml of water, are added. The solution is heated to 70 ° C and stirred vigorously for 90 minutes. After cooling to room temperature, the isopropanol phase is decanted off, the residue is adjusted to a pH of 8 and the product is precipitated with 120 ml of methanol.
- the particles formed are separated with a magnet, washed several times with water, taken up in 40 ml of water and neutralized with 3 N sodium hydroxide solution. It is then dispersed using ultrasound and concentrated on a rotary evaporator. 10 ml of a magnetic fluid with a Saturation polarization of 40 mT.
- the MF is also suitable for technical use.
- Example 6 8.1 g of ferric chloride and 3.6 g of ferric chloride are dissolved in 40 ml of water together with 0.9 g of ⁇ -cyclodextrin. About 50 ml of a 3 N sodium hydroxide solution are added with stirring until a pH of 11 is reached. The black precipitate is separated magnetically and washed several times with water, taken up in 100 ml of water and with conc. Hydrochloric acid adjusted to a pH of 1-2. The mixture is then stirred at 40 ° C for 30 min. The particles formed are separated with a magnet, washed several times with water, taken up in 30 ml of water and neutralized with 3 N sodium hydroxide solution. It is then dispersed using ultrasound and a magnetic liquid with a saturation polarization of 6 mT is obtained.
- Example 8 The particles formed are separated with a magnet, washed several times with water, taken up in 20 ml of water and neutralized with 3 N sodium hydroxide solution. The mixture is then dispersed using ultrasound and 20 ml of a magnetic liquid with a saturation polarization of 10 mT are obtained.
- Example 8 The particles formed are separated with a magnet, washed several times with water, taken up in 20 ml of water and neutralized with 3 N sodium hydroxide solution. The mixture is then dispersed using ultrasound and 20 ml of a magnetic liquid with a saturation polarization of 10 mT are obtained.
- Example 8 Example 8
- the agable particles prepared according to Example 2 are taken up in 100 ml of ethylene glycol after the water has been separated off. The small amounts of water still present in the solution are removed using a rotary evaporator.
- the magnetic fluid has a saturation polarization of 30 mT. Technically, it can be used in rotary unions.
- Example 1 Process for covalent coupling to the particles produced in Example 1 (one-step process) by adding 2 ml of magnetic liquid (... mg / ml) with an aqueous solution of 10 mg of 1-ethyl-3 - (dimethylaminopropyl) carbodiimide (EDC) in 2 ml of 0.1 2-morpholinoethanesulfonic acid monohydrate (MES) buffer in the presence of 10 mM N-hydroxysuccinimide are reacted with stirring and at room temperature. Then 2 mg streptomycin is added. The reactants are reacted for 5 hours with constant stirring and at room temperature.
- the stable magnetic fluid is diluted with 20 ml of water and has a saturation polarization of 5 mT.
- Example 12 Production of covalently bound biologically active substances according to Example 9 with the difference that in a two-stage process after the reaction of EDC and the magnetic liquid is washed twice with a 10 ml 0.1 MES buffer.
- Example 12 Production of covalently bound biologically active substances according to Example 9 with the difference that in a two-stage process after the reaction of EDC and the magnetic liquid is washed twice with a 10 ml 0.1 MES buffer.
- the stable magnetic liquids have a saturation polarization of 10 mT after dilution.
- Example 14 Preparation of core particles with a diameter of 10 nm according to Example 4 by taking up the particles in 50 ml of water and adjusting the pH to 4 with dilute hydrochloric acid.
- 1.5 g of testosterone hydroxypropyl- ⁇ -cyclodextrin (CTD.Inc) which contains 100 mg of active ingredient per 1 g of ⁇ -cyclodextrin, are added with stirring.
- the solution is stirred moderately at 35 ° C. for one hour.
- the particles are then separated with a magnet, washed several times with water, taken up in 50 ml of water and neutralized with a few drops of 3 N sodium hydroxide solution. It is then dispersed in the ultrasound.
- a biologically compatible magnetic liquid with a saturation polarization of 10 mT is obtained, which can be used for the improved local administration of testosterone in the human body.
- Example 15 Example 15
- CM-cyclodextrin magnetic fluid produced in Example 2 and an analogous magnetic fluid with carboxymethyldextran as the coating component were treated as long-term studies as follows: 4 ml each of MF were filled into Fiolax test tubes, sealed with a stopper and stored at 4 ° C. Saturation polarization and particle uptake in cell cultures were measured at the start of the test and after 10 weeks.
- CM-dextran sample With the CM-dextran sample, there was agglomeration and sedimentation in the sample tube after the end of the test and the saturation polarization of the solution decreased by 40%. The particle uptake in cell cultures decreased by 50%. In the CM-cyclodextrin sample, there were no noticeable changes from the start of the test to the end of the test.
- the particles are then magnetically separated, taken up in 20 ml of water and dispersed using ultrasound.
- the stable magnetic fluid has a saturation polarization of about 10 mT and has an above-average value of magnetic susceptibility. These magnetic fluids are particularly suitable for use in magnetic relaxation and hyperthermia.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Soft Magnetic Materials (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10154016 | 2001-10-26 | ||
DE10154016A DE10154016B4 (en) | 2001-10-26 | 2001-10-26 | Magnetic fluid and process for its manufacture |
PCT/EP2002/012037 WO2003035113A1 (en) | 2001-10-26 | 2002-10-28 | Magnetic nanodispersion comprising cyclodextrines and method for the production thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1439860A1 true EP1439860A1 (en) | 2004-07-28 |
Family
ID=7704499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02772398A Withdrawn EP1439860A1 (en) | 2001-10-26 | 2002-10-28 | Magnetic nanodispersion comprising cyclodextrines and method for the production thereof |
Country Status (8)
Country | Link |
---|---|
US (1) | US20050087719A1 (en) |
EP (1) | EP1439860A1 (en) |
JP (1) | JP2005520790A (en) |
CN (1) | CN1607963A (en) |
CA (1) | CA2464284A1 (en) |
DE (1) | DE10154016B4 (en) |
RU (1) | RU2004111602A (en) |
WO (1) | WO2003035113A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10261406A1 (en) * | 2002-12-30 | 2004-07-15 | Sustech Gmbh & Co. Kg | Process for the production of surface-coated nanoscale particles and suspensions containing them |
DE10331439B3 (en) * | 2003-07-10 | 2005-02-03 | Micromod Partikeltechnologie Gmbh | Magnetic nanoparticles with improved magnetic properties |
FR2855315B1 (en) * | 2003-05-23 | 2005-08-19 | Centre Nat Rech Scient | NEUTRAL-STABLE FERROFLUIDS AND MODIFIED FERROFLUIDS OBTAINED BY MODIFICATION OF THE PARTICLE SURFACE OF THESE FERROFLUIDS |
EP1852107A1 (en) * | 2006-04-19 | 2007-11-07 | Nanobiotix | Magnetic nanoparticles compositions and uses thereof |
US8017031B2 (en) * | 2007-01-15 | 2011-09-13 | Institute Of Chemistry, Chinese Academy Of Sciences | Biocompatible magnetic nanocrystal, powder of a biocompatible magnetic nanocrystal bearing a surface reactive group and preparations thereof |
CN101579316B (en) * | 2008-05-14 | 2012-02-29 | 陕西北美基因股份有限公司 | Preparation method of superparamagnetic cyclodextrin composite particles |
AU2012351537B2 (en) | 2011-12-16 | 2017-03-02 | Nanobiotix | Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof |
EP2647389A1 (en) | 2012-04-04 | 2013-10-09 | Charité - Universitätsmedizin Berlin | Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use |
WO2016189125A1 (en) | 2015-05-28 | 2016-12-01 | Nanobiotix | Nanoparticles for use as a therapeutic vaccine |
WO2018150362A1 (en) * | 2017-02-16 | 2018-08-23 | Vegrandis Therapeutics Pvt. Ltd. | Magnetic nanoparticle formulations for targeted delivery of drugs to lungs for treatment of pulmonary diseases |
CN109012629B (en) * | 2018-08-16 | 2021-07-30 | 南京大学 | Method for preparing magnetic carboxymethyl beta-cyclodextrin polymer and application thereof |
CN109434092B (en) * | 2018-08-31 | 2021-07-13 | 江西理工大学 | Environment-friendly dispersion solution and method for preparing neodymium iron boron magnet material by using same |
CN113234182B (en) * | 2021-05-13 | 2022-03-04 | 吉林大学 | Beta-cyclodextrin arm lectin magnetic material and preparation method and application thereof |
CN114709064B (en) * | 2022-04-02 | 2023-06-27 | 黑龙江工程学院 | Preparation method of high-saturation magnetization magnetic fluid for dynamic seal |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452773A (en) * | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
DE3443252A1 (en) * | 1984-11-23 | 1986-05-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Dextran-magnetite complexes for NMR diagnosis |
US5597531A (en) * | 1985-10-04 | 1997-01-28 | Immunivest Corporation | Resuspendable coated magnetic particles and stable magnetic particle suspensions |
DE3709851A1 (en) * | 1987-03-24 | 1988-10-06 | Silica Gel Gmbh Adsorptions Te | NMR DIAGNOSTIC LIQUID COMPOSITIONS |
ES2131067T5 (en) * | 1991-01-19 | 2004-10-16 | Meito Sangyo Kabushiki Kaisha | COMPOSITION CONTAINING ULTRAFIN PARTICLES OF MAGNETIC METAL OXIDE. |
JP3436760B2 (en) * | 1994-07-27 | 2003-08-18 | ハーバート ピルグリム | Superparamagnetic particles |
DE4428851C2 (en) * | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Nanoparticles containing iron, their production and application in diagnostics and therapy |
DE19624426A1 (en) * | 1996-06-19 | 1998-01-02 | Christian Bergemann | Magnetic particle for transport of diagnostic or therapeutic agent |
WO1998008899A1 (en) * | 1996-08-30 | 1998-03-05 | Meito Sangyo Kabushiki Kaisha | Polysaccharide derivative/magnetic metal oxide composite |
US5945293A (en) * | 1997-10-09 | 1999-08-31 | Coulter International Corp. | Protein-colloidal metal-aminodextran coated particle and methods of preparation and use |
US6231982B1 (en) * | 1997-12-10 | 2001-05-15 | Dade Behring Inc. | Particle reagents having reduced matrix effects and containing an aldehyde-reactive functional group |
SE9903183D0 (en) * | 1999-09-08 | 1999-09-08 | Europ I Of Science Ab | Selective binding and magnetically actuated nanoparticles for medical use |
-
2001
- 2001-10-26 DE DE10154016A patent/DE10154016B4/en not_active Expired - Fee Related
-
2002
- 2002-10-28 JP JP2003537677A patent/JP2005520790A/en not_active Withdrawn
- 2002-10-28 RU RU2004111602/15A patent/RU2004111602A/en not_active Application Discontinuation
- 2002-10-28 CA CA002464284A patent/CA2464284A1/en not_active Abandoned
- 2002-10-28 WO PCT/EP2002/012037 patent/WO2003035113A1/en not_active Application Discontinuation
- 2002-10-28 US US10/493,954 patent/US20050087719A1/en not_active Abandoned
- 2002-10-28 CN CNA028260686A patent/CN1607963A/en active Pending
- 2002-10-28 EP EP02772398A patent/EP1439860A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO03035113A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003035113A1 (en) | 2003-05-01 |
CN1607963A (en) | 2005-04-20 |
CA2464284A1 (en) | 2003-05-01 |
DE10154016A1 (en) | 2003-05-15 |
RU2004111602A (en) | 2005-10-20 |
DE10154016B4 (en) | 2004-02-12 |
US20050087719A1 (en) | 2005-04-28 |
JP2005520790A (en) | 2005-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Aisida et al. | Bio-inspired encapsulation and functionalization of iron oxide nanoparticles for biomedical applications | |
EP0186616B1 (en) | Magnetic particles for diagnostic purposes | |
EP1644941B1 (en) | Method of manufacturing magnetic nanoparticles having improved magnetic properties | |
DE69203004T2 (en) | Composition for increasing the image contrast when generating images from the digestive tract of patients. | |
DE69909090T2 (en) | NUCLEAR GENERATION AND GROWTH OF METAL OXIDE NANOPARTICLES AND USE | |
DE3751918T2 (en) | BIODEGRADABLE SUPER-PARAMAGNETIC MATERIAL FOR USE IN CLINICAL APPLICATIONS | |
DE10154016B4 (en) | Magnetic fluid and process for its manufacture | |
DE4117782C2 (en) | Nanocrystalline magnetic iron oxide particles, processes for their production and diagnostic and / or therapeutic agents | |
Santiago-Rodríguez et al. | Synthesis, stability, cellular uptake, and blood circulation time of carboxymethyl-inulin coated magnetic nanoparticles | |
Ramasamy et al. | Molecular encapsulator on the surface of magnetic nanoparticles. Controlled drug release from calcium Ferrite/Cyclodextrin–tethered polymer hybrid | |
Miao et al. | Stable and non-toxic ultrasmall gadolinium oxide nanoparticle colloids (coating material= polyacrylic acid) as high-performance T 1 magnetic resonance imaging contrast agents | |
US20100168044A1 (en) | Superparamagnetic nanoparticle encapsulated with stimuli responsive polymer for drug delivery | |
DE4428851A1 (en) | Nanoparticles containing iron, their production and application in diagnostics and therapy | |
EP0888545A1 (en) | Super-paramagnetic particles with increased r 1? relaxivity, processes for producing said particles and use thereof | |
CN107961378B (en) | Preparation method and application of magnetic graphene oxide-chitosan/glucan compound | |
WO2009137964A1 (en) | Preparation of superparamagnetic composite microparticles from cyclodextrin | |
CN111601622A (en) | Preparation method of preparation based on iron oxide magnetic nanoparticles for magnetic resonance imaging diagnosis of tumors | |
DE19624426A1 (en) | Magnetic particle for transport of diagnostic or therapeutic agent | |
EP1799268B2 (en) | Magnetic particles for therapy and diagnosis | |
DE102004035803B4 (en) | Process for the preparation of water-dispersed iron oxide nanoparticles and their use | |
US20120121717A1 (en) | DRUG-LOADED POLYSACCHARIDE-COATED GOLDMAG PARTICLES (DPGPs) AND ITS SYNTHESIS METHOD | |
Spiridonov et al. | Water-Soluble magnetic nanocomposites based on carboxymethyl cellulose and iron (III) oxide | |
BRPI0105499B1 (en) | process for obtaining composites composed of particulate materials and cyclodextrins and / or products derived from | |
DE10205332B4 (en) | Process for the production of magnetic nanoparticles | |
Manikantan et al. | Praseodymium metal nanorods as a 5-fluorouracil carrier |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17P | Request for examination filed |
Effective date: 20040416 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GOETZE, THOMAS Inventor name: BUSKE, NORBERT Inventor name: GANSAU, CHRISTIAN |
|
17Q | First examination report despatched |
Effective date: 20050308 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050920 |